+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Nocturia Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook

  • ID: 5130069
  • Report
  • July 2020
  • Region: Global
  • 45 Pages
  • VPA Research


  • Ferring Pharmaceuticals
  • Roivant Sciences Ltd
  • Tacurion Pharma Inc

Nocturia is one of the widely researched conditions during 2020 with 5 companies actively focusing on realizing pipeline’s potential. Development of Nocturia medicines is identified as integral to the strategy of the majority of companies operating in the industry.

Global Nocturia market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Nocturia.

Good progress is anticipated during 2020 and 2021 with Nocturia pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Nocturia pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.


The “Nocturia pipeline Research Monitor, 2020” report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.

This Nocturia pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.

The competitive intelligence report on Nocturia presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Nocturia pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.


Nocturia development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided:
  • Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.
  • Phase of development
  • Mechanism of Action
  • Route of Administration
  • Companies involved including originator, licensing companies, developer, investors, and others
  • New molecular entity details
  • Orphan drug designation and other special status provided by regulators


Both small size and large size pharmaceutical companies are investing their resources in Nocturia drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Nocturia. Partnerships and acquisitions are also increasingly observed in the pipeline.

This research report presents an analysis of 5 Nocturia companies including company overview, key snapshot, contact information, and their strategies on accelerating Nocturia pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.

Companies analyzed in the report include- Ferring Pharmaceuticals, Roivant Sciences Ltd, Sanwa Kagaku Kenkyusho Co Ltd, Tacurion Pharma Inc, Wellesley Pharmaceuticals LLC

Reasons to Buy
  • The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.
  • This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data
  • Buyers can identify most promising drug candidates for treatment of Nocturia
  • It allows users to strengthen their pipeline through acquisitions, licensing and collaborations
  • Users can estimate possible delays in the delivery of pipeline or launch of new products
  • Stay ahead of competition through understanding their pipeline progression, strategies and outlook
  • The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.
  • Optimize your licensing and technology transfer strategies through identification of prospect partners
Note: Product cover images may vary from those shown


  • Ferring Pharmaceuticals
  • Roivant Sciences Ltd
  • Tacurion Pharma Inc

1. Introduction to Nocturia
1.1 Nocturia- Disease overview
1.2 Nocturia- Market Size
1.3 Nocturia- Companies Involved
2. Nocturia Pipeline Snapshot- 2020
2.1 Nocturia Pipeline by Phase
2.2 Nocturia Pipeline by Mechanism of Action
2.3 Nocturia Pipeline by Route of Administration
2.4 Nocturia Pipeline- New Molecular Entities
2.5 Nocturia Pipeline- Orphan Drug Designation/ Special Designation
3. Nocturia Drug Profiles
3.1 Current Status
3.2 Nocturia Drug Snapshot
3.3 Nocturia Therapeutic Candidates- Originator/Licensor
3.4 Route of Administration
3.5 Mechanism of Action
3.6 NME
4. Company wise Pipeline and Trials
4.1 Ferring Pharmaceuticals Nocturia Pipeline Insights and Clinical Trials
4.2 Roivant Sciences Ltd Nocturia Pipeline Insights and Clinical Trials
4.3 Sanwa Kagaku Kenkyusho Co Ltd Nocturia Pipeline Insights and Clinical Trials
4.4 Tacurion Pharma Inc Nocturia Pipeline Insights and Clinical Trials
4.5 Wellesley Pharmaceuticals LLC Nocturia Pipeline Insights and Clinical Trials
5. Nocturia Market News and Updates
6. Appendix
6.1 Sources and Methodology
6.2 Contact Information
Note: Product cover images may vary from those shown
  • Ferring Pharmaceuticals
  • Roivant Sciences Ltd
  • Sanwa Kagaku Kenkyusho Co Ltd
  • Tacurion Pharma Inc
  • Wellesley Pharmaceuticals LLC
Note: Product cover images may vary from those shown